TimesSquare Capital Management LLC Trims Stake in Repligen Corporation (NASDAQ:RGEN)

TimesSquare Capital Management LLC lowered its position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 9.6% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 235,987 shares of the biotechnology company's stock after selling 25,005 shares during the period. TimesSquare Capital Management LLC owned about 0.42% of Repligen worth $30,027,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. KBC Group NV raised its stake in shares of Repligen by 14.9% during the first quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock valued at $324,000 after acquiring an additional 329 shares during the last quarter. LPL Financial LLC increased its holdings in Repligen by 47.6% during the 4th quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company's stock valued at $4,873,000 after purchasing an additional 10,395 shares during the period. Signaturefd LLC raised its position in Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 124 shares during the last quarter. GAMMA Investing LLC raised its position in Repligen by 40.1% during the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock valued at $122,000 after purchasing an additional 274 shares during the last quarter. Finally, Zions Bancorporation N.A. lifted its holdings in Repligen by 48.9% in the 4th quarter. Zions Bancorporation N.A. now owns 14,079 shares of the biotechnology company's stock worth $2,027,000 after buying an additional 4,626 shares during the period. Institutional investors own 97.64% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on RGEN. Barclays assumed coverage on Repligen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $150.00 target price on the stock. Royal Bank Of Canada decreased their price objective on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 target price on shares of Repligen in a research report on Monday, May 5th. Canaccord Genuity Group cut their target price on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research note on Wednesday, April 16th. Finally, Wall Street Zen downgraded shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $170.75.

Repligen Stock Up 3.6%

Shares of RGEN stock traded up $4.29 during trading hours on Thursday, hitting $124.04. 582,585 shares of the company's stock traded hands, compared to its average volume of 726,948. The company has a quick ratio of 5.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.27. The stock's fifty day simple moving average is $124.79 and its two-hundred day simple moving average is $138.70. Repligen Corporation has a 12-month low of $102.97 and a 12-month high of $182.52. The stock has a market cap of $6.97 billion, a price-to-earnings ratio of -275.64, a PEG ratio of 3.43 and a beta of 1.11.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The business had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. During the same period last year, the business earned $0.28 EPS. Repligen's revenue was up 10.4% compared to the same quarter last year. On average, analysts expect that Repligen Corporation will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.